First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. (Q35905061)
Jump to navigation
Jump to search
scientific article published on 31 January 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. |
scientific article published on 31 January 2011 |
Statements
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia (English)
Eric J Feldman
Jeffrey E Lancet
Jonathan E Kolitz
Ellen K Ritchie
Gail J Roboz
Ekatherine Asatiani
Lawrence D Mayer
Christine Swenson
Arthur C Louie
31 January 2011